Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSCs for Prevention of Heart Failure after AMI
NCT05043610Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Sep 2021
- Primary completion
- Nov 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of wharton's jelly mesenchymal stromal cells in heart failure (HF) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Incidence of Heart Failure at 3 years. Started Sep 2021; status: completed.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05043610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043610.